On July 6, 2026, Belite Bio, Inc (NASDAQ: BLTE), a company specializing in developing drugs for degenerative retinal diseases, revealed its upcoming participation in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026, at 12:30 pm ET. Belite Bio focuses on creating innovative therapeutics for these conditions due to their substantial unmet medical needs.